XML 22 R7.htm IDEA: XBRL DOCUMENT
v3.25.1

Organization and Nature of Business | 3 Months Ended
--- | ---
Mar. 31, 2025
Organization and Nature of Business [Abstract] |
Organization and nature of business |
(1) | Organization and nature of business
The condensed consolidated financial statements of OSR Holdings, Inc. (the “Company” or the “Parent”) and its subsidiaries (collectively, the “Group”) for the period ended March 31, 2025 were authorized for issuance in accordance with a resolution of the directors meeting on May 7, 2025. The registered office is located at 37-36 Hoedong-gil, Paju-si, Gyeongi-do, Republic of Korea. The Company is a global life sciences holding company based in South Korea and is actively engaging in drug development, dedicating to advance healthcare outcome and driving social progress. Through open innovation and responsible investment, the Company aims to make a lasting impact across the industry as well as our society. With a strong focus on oncology and immunology, the Company’s mission is to build a robust portfolio of ventures, bringing innovative and transformative therapies to market. Details of shareholders as of March 31, 2025 are as follows:
Name of Shareholder |  | Number of ordinary share |  |  | Percentage of ownership |
Bellevue Global Life Sciences Investors LLC |  |  | 1,332,500 |  |  |  | 6.91 | %
Bellevue Capital Management Europe AG |  |  | 8,612,634 |  |  |  | 44.68 | %
Bellevue Capital Management LLC |  |  | 3,123,970 |  |  |  | 16.21 | %
Duksung Co.,Ltd. |  |  | 1,420,215 |  |  |  | 7.37 | %
Others |  |  | 4,787,659 |  |  |  | 25.68 | %
Total |  |  | 19,276,978 |  |  |  | 100.00 | %
Details of investments in subsidiaries as of March 31, 2025 are as follows:
Name of subsidiary |  | Share capital |  |  | Percentage of ownership |  |  | Principal activities |  | Country of incorporation
VAXIMM AG (“VAXIMM”) |  |  | 1,091,203,754 |  |  |  | 100.00 | % |  | Biotech (drug development) |  | Switzerland
RMC Co., Ltd. (“RMC”) |  |  | 35,000,000 |  |  |  | 100.00 | % |  | Medical device distribution |  | Republic of Korea
Darnatein Co., Ltd. (“Darnatein”) |  |  | 6,466,667,000 |  |  |  | 100.00 | % |  | Biotech (drug development) |  | Republic of Korea
OSR Holdings, Inc. |  |  | 2,826,969 |  |  |  | 100.00 | % |  | SPAC |  | The United States
Key financial information of the subsidiaries at March 31, 2025 are as follows :
Name of subsidiary |  | Asset |  |  | Liability |  |  | Equity |  |  | Sales |  |  | Net Income (loss) |
VAXIMM AG |  | $ | 910,415 |  |  | $ | 386,254 |  |  | $ | 524,161 |  |  | $ | - |  |  | $ | (78,609 | )
RMC Co.,Ltd |  |  | 2,040,181 |  |  |  | 1,568,695 |  |  |  | 471,486 |  |  |  | 761,272 |  |  |  | (211,541 | )
Darnatein Co.,Ltd |  |  | 110,171 |  |  |  | 678,651 |  |  |  | (568,481 | ) |  |  | - |  |  |  | (141,742 | )
OSR Holdings, Inc. |  |  | 1,687,119 |  |  |  | 10,071,814 |  |  |  | (8,384,695 | ) |  |  | - |  |  |  | - |
Summaries of entities, which are newly included in consolidation scope for the periods ended March 31, 2025 and 2024 are as follows:
For the year ended March 31, 2025
Name of subsidiary |  | Reason |  | Type of purchase consideration
OSR Holdings, Inc. |  | Acquisition (*1) |  | Equity swap with shares of the Parent and OSR inc.’s share
(*1) | The Parent acquired subsidiary in February 2025 and accounted for the acquisitions at March 31, 2025, which is deemed the acquisition date.

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContent Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration